Related Experiment Video
Updated: Jul 19, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Predicting treatment response in chronic, acquired demyelinating neuropathies
Yee-Cheun Chan1, Einar Wilder-Smith
1National University Hospital, Division of Neurology, 5 Lower Kent Ridge Road, 119074 Sinagpore. yeecheun@yahoo.com.sg
Expert Review of Neurotherapeutics
|November 3, 2006
Summary
Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an immune disorder. This review details CIDP subtypes, their clinical paths, and responses to immunomodulatory treatments, aiding in personalized therapy selection.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Background:
- Chronic inflammatory demyelinating polyradiculopathy (CIDP) is an immune-mediated neuropathy.
- Over 30 years, diverse CIDP phenotypes, clinical courses, and treatment responses have emerged.
- New therapeutic agents show promise for managing CIDP.
Purpose of the Study:
- To review current knowledge on CIDP.
- To summarize clinical courses and treatment responses across CIDP subgroups.
- To identify predictors of treatment response in CIDP.
Main Methods:
- Literature review of studies on CIDP.
- Analysis of clinical data from various CIDP phenotypes.
- Synthesis of information on immunomodulatory treatments and their efficacy.
Main Results:
- CIDP presents a spectrum of clinical presentations and disease progression.
- Treatment responses vary significantly among different CIDP subgroups.
- Predictors for treatment response are being identified, guiding therapeutic choices.
Conclusions:
- Understanding CIDP heterogeneity is crucial for effective management.
- Personalized treatment strategies based on subgroup characteristics and response predictors are essential.
- Further research into novel therapies and predictive markers for CIDP is warranted.
